时间标签:数据日期 2026-10-28 · 生成时间 2026-10-31 05:30(Asia/Shanghai)| 档位:观察哨39 | 窗口 T-3 | 上游评级 C
这项研究想回答什么
萝卜硫素的神经退行相关靶点能否用硅基流程排出优先级?
方法与数据
转录组分析 + 多准则靶点优先级 + AutoDock Vina 对接 + 分子动力学与 MM-GBSA(GRIK2 ΔG_bind=-19.78、FABP3 -14.49 kcal/mol)。
核心结论
以下所有数字均可在官方 abstract 原文(见第 7 节)中逐字核对;上游未给出的定量一律写「未给出」,不估算、不换算。
- 一句话贡献:R-/S-萝卜硫素对接 693 个优先靶点,88 个预测 ΔG ≤ -4.0 kcal/mol,其中 65 个(73.9%)在 GTEx 至少一个脑区表达;独立交叉验证显示在 SFN 响应性 AD 转录组数据集中富集(OR=1.44,95% CI 1.08–1.89,p=0.0104)。
局限与未核验项
纯计算流程、无任何湿实验验证;核心富集效应量弱(OR 1.44,CI 下限 1.08 逼近无效线)。
补全文时优先核:若跟进:需看是否有后续湿实验验证、对接打分与实测亲和力的相关性、693 个靶点的筛选标准。
⚠️ 本页为摘要级解读:未取得 PDF 全文,上述所有结论均未核至 Results/Methods;效应量、样本量、统计方法与多重比较校正在多数条目中仍未知。
对本领域的价值
萝卜硫素属常见"抗衰/神经保护"叙事,但本研究全硅基且对衰老仅间接相关,属长尾命中,仅宜作假设来源。
编辑研判
萝卜硫素是「抗衰/神经保护」叙事里的常客,但本条全硅基、且核心富集效应量偏弱(OR 1.44,95% CI 1.08–1.89,CI 下限逼近无效线),只能当假设来源,不能当证据。可留用的是流程本身:转录组分析 → 多准则靶点优先级 → AutoDock Vina 对接 → MD 与 MM-GBSA(GRIK2 ΔG_bind=−19.78、FABP3 −14.49 kcal/mol),这套低成本排序对我们快速扫天然产物候选是可复用的。无任何湿实验验证。
官方摘要原文(逐字,供回溯)
展开 api.biorxiv.org / api.medrxiv.org 返回的 abstract 原文
Sulforaphane (SFN), a natural isothiocyanate from cruciferous vegetables, exerts neuroprotective effects through mechanisms extending beyond canonical Nrf2/ARE activation. Here, we developed a multi-dataset computational framework integrating transcriptomic analysis, multi-criteria target prioritization, and structural docking evaluation. R- and S-SFN were docked against 693 prioritized targets using AutoDock Vina, followed by cross-validation, brain expression profiling, and molecular dynamics simulations. Four genes (IGSF9, KCNQ5, KCTD12, and NFIX) were dysregulated across all four datasets. Among 693 targets, 88 showed favorable predicted docking scores (deltaG less than or equal to -4.0 kcal/mol), with 65 (73.9%) exhibiting expression in at least one GTEx brain region. Independent cross-validation showed significant enrichment of prioritized targets in an SFN-responsive Alzheimer disease transcriptomic dataset (OR = 1.44, 95% CI: 1.08-1.89, p = 0.0104). Complementary disease gene set enrichment confirmed that 33% of strong hits (29/88) overlap established neurodegeneration gene sets across AD, PD, and ALS - including ACHE, target of FDA-approved anti-AD drugs - with highly significant enrichment across all three disease categories (OR range: 67-127, all p less than 0.001). R-SFN showed a modest but statistically detectable preference over S-SFN across the 88 strong hits (Wilcoxon p = 0.0081; paired t-test p = 0.0047). TMEM45A, GRIK2, and FABP3 emerged as putative neurodegeneration-relevant targets. Molecular dynamics simulations supported the structural stability of R-SFN poses for TMEM45A, GRIK2, and FABP3, while MM-GBSA estimated favorable binding energies for GRIK2 (deltaG_bind = -19.78 kcal/mol) and FABP3 (deltaG_bind = -14.49 kcal/mol). These findings generate testable hypotheses regarding previously underexplored molecular targets that may contribute to the neuroprotective actions of SFN.
本文为预印本,未经同行评审,结论可能在正式发表时变更。生成任务 12819187(预印本全文级解读)· 上游 12784209(预印本速递)。
C 级证据分级:C 级(预印本,未经同行评审;本页为摘要级,未核至全文)
本文为预印本,未经同行评审;且本页为「摘要级」——未取得 PDF 全文(源站封锁),全部结论只依据官方 API 摘要原文。效应量、样本量、统计方法与多重比较校正在多数条目中仍未知,摘要未给出之处一律写「未给出」/「待补全文」,未做任何数值推算补全。
关于本文的文献来源:本站依据元层《预印本全文级解读_2026-10-31》(上游《预印本速递_2026-10-31》)撰写,附官方 abstract 原文供逐字回溯。